Tahoe Therapeutics Raises $30M to Develop Billion-Point AI Cell Model Dataset

Tahoe Therapeutics, a San Francisco-based biotech startup, has raised $30 million in a funding round led by Amplify Partners, bringing its valuation to $120 million. The company specializes in developing AI-powered virtual cell models aimed at transforming drug discovery, particularly for cancer, by digitally simulating how cells respond to various drug molecules. Tahoe's proprietary Mosaic platform generates large-scale datasets, such as the recently released Tahoe-100M, which contains over 100 million datapoints and has been downloaded nearly 100,000 times by researchers globally. With the new capital, Tahoe plans to expand its dataset to over one billion single-cell datapoints, mapping millions of drug-patient interactions to improve the predictive accuracy of AI models and reduce clinical trial failures. The startup is also exploring strategic collaborations with pharmaceutical and AI companies to accelerate clinical translation and the development of precision medicines. The initiative represents a significant step toward leveraging AI to overcome longstanding challenges in drug discovery by providing granular, high-quality biological data that supports more effective therapeutic development.